Introduction
Staquis® (crisaborole 2%) is the first non-steroidal, topical PDE4 inhibitor indicated for
treatment of mild to moderate atopic dermatitis in patients 3 months of age and older.
1,13
Staquis® inhibits phosphodiesterase 4 (PDE4), thereby decreasing the release of inflammatory cytokines. 3
A PDE4 inhibitor, Staquis® is delivered via an emollient-rich vehicle1. It is thought to help control inflammation and help lock in moisture to soften the skin.3
Treating AD through PDE4 inhibition
Staquis® penetrates the skin and inhibits PDE4 within cells.4
PDE4 inhibition results in increased intracellular levels of cyclic adenosine monophosphate (cAMP), which may reduce inflammatory cytokines that contribute to the signs and symptoms of AD.4,5
The specific mechanism(s) by which Staquis® exerts its therapeutic action is currently not well defined.1